Got Stocks from QualityStocks Ones To Watch

Got Stocks

Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...

Untitled Document

Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma, Inc. develops novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The company utilizes innovative technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The design of these technologies, including its nucleoside chemistry expertise and market-centered approach to drug discovery, are to efficiently deliver small molecule therapeutics, which are safe, effective, and convenient to administer. A biotechnology company, Cocrystal Pharma has offices in Tucker, Georgia and Bothell, Washington.

The company's proprietary technologies revolve around a structure-based drug discovery strategy teamed up with extensive nucleoside experience. Employing techniques called protein cocrystallization and X-ray crystallography, Cocrystal Pharma quickly identifies novel binding sites, identifies critical inhibitor-protein interactions, and optimizes the structure of the inhibitor in a highly rapid iterative fashion.

Cocrystal Pharma has identified promising, preclinical stage antiviral compounds for unmet medical needs. These include hepatitis, influenza, as well as norovirus infections. The company is developing a series of compounds that are potent non-nucleoside and nucleoside inhibitors of hepatitis C NS5B RNA dependent RNA polymerase, a replication enzyme vital to viral replication and are highly conserved between all hepatitis C genotypes. Consequently, inhibitors of this enzyme are likely to have multi- or pan-genotypic activity.

Furthermore, Cocrystal Pharma is developing compounds that inhibit hepatitis C helicase and NS5A, two enzymes vital for viral replication. Additionally, the company has identified a picomolar inhibitor of NS5A, another important viral replication protein. Its compounds that target NS5B hepatitis C polymerase, NS5A, and NS3 helicase will undergo development as a combination treatment.

Cocrystal Pharma previously announced the successful completion and positive data from the Phase 1a/1b study for its lead broad spectrum compound, CC-31244, in healthy volunteers and in hepatitis C virus (HCV)-infected individuals. CC-31244 is a broad-spectrum, potent NS5B non-nucleoside inhibitor (NNI) of HCV replication with a high barrier to resistance. There were no dose-limiting adverse events, study discontinuations because of adverse events, or serious adverse events reported.

Cocrystal Pharma announced in September of 2017 that it entered into a research collaboration with HitGen, Ltd., a private biotechnology company and InterX, Inc., a private computer software company, to develop small molecule drug candidates against several undisclosed targets.

Through the collaboration, Cocrystal Pharma, HitGen, and InterX scientists will apply HitGen's DNA-encoded library (DEL) technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs.

The DEL technology enables a large number of compounds to be quickly identified for specific drug targets. Cocrystal Pharma will utilize its industrialized crystallization and co-crystallization technology to determine at near atomic resolution the structures of HitGen's selected library compounds that interact with drug targets. Also, InterX will utilize its advanced proprietary software to design superior drugs from the information provided by Cocrystal Pharma and HitGen.




The QualityStocks

Read the articles covering the biggest movers in the markets today.



Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.


The QualityStocks Daily

Go back to see our previous newsletters and find out what you might have missed.